Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Invokana

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

National Institute for Health and Care Excellence NICE logo

AstraZeneca’s Forxiga set to be recommended by NICE

The type 2 diabetes ‘triple therapy’ is backed in draft guidance

- PMLiVE

GSK and J&J file sirukumab for rheumatoid arthritis in EU

If approved it will compete with Roche blockbuster Actemra

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

- PMLiVE

J&J and Hanmi collaborate on diabetes and obesity

Alliance worth up to$915m

- PMLiVE

J&J buys firm seeking hepatitis B cure

Acquires Philadelphia-based Novira therapeutics

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

Sidestep into Crohn’s could help Stelara cope with new competition

Filing for new indication expected before year's end

- PMLiVE

J&J’s share buyback ‘doesn’t prevent acquisitions’

Comes as company reports 7.4% decrease in sales

- PMLiVE

J&J’s Invokana receives new FDA safety warning

Additional trial data highlights bone problems

- PMLiVE

JWT turns to Oscar nominee for Listerine campaign

Produces short online film and app for J&J's mouthwash brand

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links